Company profile: Freenome
1.1 - Company Overview
Company description
- Provider of blood-based tests and clinical studies for early cancer detection to improve access to routine screening, including PREEMPT CRC for colorectal cancer and the PROACT LUNG study using a blood test. Runs the Vallania and Sanderson studies targeting multiple cancers, pairing real-world data with multiomics; partners with Walgreens to increase research diversity; and acquired Oncimmune Ltd to enhance its cancer detection portfolio.
Products and services
- PREEMPT CRC (blood-based): Detects early colorectal cancer using a blood test to expand access to routine screening, focusing on early identification of colorectal malignancies
- Sanderson Study (multiomics): Pairs real-world data with multiomics for detection of multiple cancers, enabling research that connects real-world datasets and multiomic analyses for cancer detection
- PROACT LUNG (blood-based): Runs a clinical study for early detection of lung cancer using a blood test, assessing blood-test approaches for early lung cancer detection.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Freenome
Kudos Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development based on the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kudos Pharmaceuticals company profile →
Beacon Biomedical
HQ: United States
Website
- Description: Provider of easy, accurate, and affordable blood-based tests for earlier cancer detection, developing and commercializing waived test (LDT) solutions for healthcare practitioners and individuals. Offerings include BeScreened-CRC, a blood-based colorectal cancer screening test for adults 45+ who are unwilling or unable to undergo traditional screening methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Beacon Biomedical company profile →
Allarity
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology therapies and predictive diagnostics for personalized cancer treatment, utilizing DRP Technology to predict patient response and refine patient selection. Pipeline includes Dovitinib for renal cell carcinoma, Stenoparib, LiPlaCis, and 2X-111.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allarity company profile →
Seagen
HQ: United States
Website
- Description: Provider of monoclonal antibody-based therapies and advanced antibody-drug conjugate technology focused on improving patient outcomes in cancer and autoimmune diseases. Lead program SGN-35 is in a pivotal trial for patients with relapsed or refractory Hodgkin lymphoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seagen company profile →
Gloucester Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical development, acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization; owned by Celgene. Its first compound, romidepsin, is a late-stage oncology drug candidate.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gloucester Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Freenome
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Freenome
2.2 - Growth funds investing in similar companies to Freenome
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Freenome
4.2 - Public trading comparable groups for Freenome
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →